Levocet M Syrup is a combination pharmaceutical formulation containing Levocetirizine dihydrochloride 2.5 mg and Montelukast sodium 4 mg per 5 ml suspension, designed for the management of allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively antagonizes peripheral H1 histamine receptors, thereby alleviating symptoms such as sneezing, rhinorrhea, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene D4 receptor, reducing bronchoconstriction, inflammation, and mucus secretion commonly observed in asthma and allergic rhinitis. The synergistic action of Levocetirizine and Montelukast provides comprehensive relief from allergic manifestations by targeting multiple inflammatory pathways. Levocet M Syrup is indicated for pediatric and adult patients suffering from allergic rhinitis, chronic urticaria, and mild to moderate asthma, offering improved symptom control and enhanced quality of life. The syrup formulation ensures ease of administration, particularly in pediatric populations. Dosage should be individualized based on age, severity of symptoms, and clinical response, with adherence to prescribed guidelines to minimize adverse effects. Common side effects may include headache, drowsiness, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment. Levocet M Syrup should be used under medical supervision.